Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521062 | 0.88 | ROCK2 (0.80) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4515679 | 0.88 | ROCK2 (0.79) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2445126 | 0.87 | ROCK2 (0.69) | ROCK2ROCK1SMN1; SMN2NT5EPOLB | |
| Hydrochloric Acid SCHEMBL4517331 | 0.87 | ROCK2 (0.78) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4517142 | 0.86 | ROCK2 (0.84) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4518105 | 0.86 | ROCK2 (0.73) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4515869 | 0.86 | ROCK2 (0.72) | ROCK2ROCK1SMN1; SMN2NT5EPOLB | |
| SCHEMBL4523166 | 0.85 | ROCK2 (0.66) | ROCK2ROCK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14246056 | 0.85 | ROCK2 (0.70) | ROCK2PLAU | |
| SCHEMBL14245461 | 0.85 | ROCK2 (0.65) | ROCK2ROCK1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | claimed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | claimed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | claimed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | ROCK2 32/4885ROCK1 1/4885SMN1; SMN2 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.